Phase I Study in Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Patients to Determine the Recommended Dose of the Investigational Product (CYAD-02)
Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome Interventions: Biological: CYAD-02; Drug: ENDOXAN; Drug: Fludara Sponsor: Celyad (formerly named Cardio3 BioSciences) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Acute Leukemia | Acute Myeloid Leukemia | Cardiology | Heart | Leukemia | Myelodysplastic Syndrome | Research | Study